Copyright © 2000 by the European Society of Cardiology.
Editorial
May aspirin be replaced in the treatment of myocardial infarction?
Catalan Institut of Cardiology, Hospital Sant Pau, Barcelona, Spain
References
- Maseri A. Ischemic Heart Disease. New York: Churchill Livingstone Inc; 1995.
- Knight CJ. New insights into the pathophysiology of acute coronary occlusion. Eur Heart J. 1999;Suppl F:F3F6
- Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657671
[Free Full Text] - Cairns JA. Antithrombotic agents in coronary artery disease. Chest. 1998;114:611S633S[Medline]
- Trip MD, Cats VM, van Capeller JFL, Vreeken J. Platelet hyper-reactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:15491554[Abstract]
- Schrör K. Antiplatelet drugs. A Comparative review. Drugs. 1995;50:728[Web of Science][Medline]
- Cruz-Fernández JM, López-Bescós O, García-Dorado D. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J. 2000;21:457465
[Abstract/Free Full Text] - Lancet. August 1988;2:349360[Medline]
- Kaski JC, Plaza Celemin L. Antiplatelet treatment in acute coronary syndromes. Eur Heart J. 1999;Suppl F:
- Br Med J. 1994;308:81106
[Abstract/Free Full Text] - Topol EJ, Byzova TV, Plow EF. Platelet GPIIB-IIIa blockers. Lancet. 1999;353:227321[CrossRef][Web of Science][Medline]
- McNeely W, Goa KL. Triflusal. Drugs. 1998;55:823833[CrossRef][Web of Science][Medline]
- Lancet. 1996;348:13291339[CrossRef][Web of Science][Medline]
- Bayón Y, Alonso A, Sánchez-Crespo M. 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potential inhibitors of nuclear factor kB activation. Br J Pharmacol. 1999;126:13591366[CrossRef][Web of Science][Medline]
- Fernández de Arriba A, Cavalcanti F, Miralles A. Inhibition of cyclooxygenase-2 expression by 4trifluoromethyl derivative of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoacid. Mol Pharmacol. 1999;4:753761
This article has been cited by other articles:
![]() |
J.C. Kaski and E.G. Zouridakis Inflammation, infection and acute coronary plaque events Eur. Heart J. Suppl., August 1, 2001; 3(suppl_I): I10 - I15. [Abstract] [PDF] |
||||
![]() |
J.M. Cruz-Fernandez Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors Eur. Heart J. Suppl., August 1, 2001; 3(suppl_I): I23 - I30. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
